Development of potent and selective Plasmodium falciparum calcium-dependent protein kinase 4 (PfCDPK4) inhibitors that block the transmission of malaria to mosquitoes

Rama Subba Rao Vidadala, Kayode K. Ojo, Steven Johnson, Zhongsheng Zhang, Stephen E. Leonard, Arinjay Mitra, Ryan Choi, Molly C. Reid, Katelyn R. Keyloun, Anna M W Fox, Mark Kennedy, Tiffany Silver-Brace, Jen C C Hume, Stefan Kappe, Christophe L M J Verlinde, Erkang Fan, Ethan A. Merritt, Wesley C. Van Voorhis, Dustin J. Maly

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Malaria remains a major health concern for a large percentage of the world's population. While great strides have been made in reducing mortality due to malaria, new strategies and therapies are still needed. Therapies that are capable of blocking the transmission of Plasmodium parasites are particularly attractive, but only primaquine accomplishes this, and toxicity issues hamper its widespread use. In this study, we describe a series of pyrazolopyrimidine- and imidazopyrazine-based compounds that are potent inhibitors of PfCDPK4, which is a calcium-activated Plasmodium protein kinase that is essential for exflagellation of male gametocytes. Thus, PfCDPK4 is essential for the sexual development of Plasmodium parasites and their ability to infect mosquitoes. We demonstrate that two structural features in the ATP-binding site of PfCDPK4 can be exploited in order to obtain potent and selective inhibitors of this enzyme. Furthermore, we demonstrate that pyrazolopyrimidine-based inhibitors that are potent inhibitors of the in vitro activity of PfCDPK4 are also able to block Plasmodium falciparum exflagellation with no observable toxicity to human cells. This medicinal chemistry effort serves as a valuable starting point in the development of safe, transmission-blocking agents for the control of malaria.

Original languageEnglish (US)
Pages (from-to)562-573
Number of pages12
JournalEuropean Journal of Medicinal Chemistry
Volume74
DOIs
StatePublished - Mar 3 2014
Externally publishedYes

Fingerprint

Plasmodium falciparum
Protein Kinase Inhibitors
Culicidae
Malaria
Plasmodium
Toxicity
Primaquine
Parasites
Enzyme Inhibitors
Sexual Development
Pharmaceutical Chemistry
Protein Kinases
Adenosine Triphosphate
Binding Sites
Cells
Health
Calcium
calcium-dependent protein kinase
Mortality
Therapeutics

Keywords

  • Exflagellation
  • PfCDPK1
  • PfCDPK4
  • Plasmodium falciparum
  • Pyrazolopyrimidine

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Pharmacology

Cite this

Development of potent and selective Plasmodium falciparum calcium-dependent protein kinase 4 (PfCDPK4) inhibitors that block the transmission of malaria to mosquitoes. / Vidadala, Rama Subba Rao; Ojo, Kayode K.; Johnson, Steven; Zhang, Zhongsheng; Leonard, Stephen E.; Mitra, Arinjay; Choi, Ryan; Reid, Molly C.; Keyloun, Katelyn R.; Fox, Anna M W; Kennedy, Mark; Silver-Brace, Tiffany; Hume, Jen C C; Kappe, Stefan; Verlinde, Christophe L M J; Fan, Erkang; Merritt, Ethan A.; Van Voorhis, Wesley C.; Maly, Dustin J.

In: European Journal of Medicinal Chemistry, Vol. 74, 03.03.2014, p. 562-573.

Research output: Contribution to journalArticle

Vidadala, RSR, Ojo, KK, Johnson, S, Zhang, Z, Leonard, SE, Mitra, A, Choi, R, Reid, MC, Keyloun, KR, Fox, AMW, Kennedy, M, Silver-Brace, T, Hume, JCC, Kappe, S, Verlinde, CLMJ, Fan, E, Merritt, EA, Van Voorhis, WC & Maly, DJ 2014, 'Development of potent and selective Plasmodium falciparum calcium-dependent protein kinase 4 (PfCDPK4) inhibitors that block the transmission of malaria to mosquitoes', European Journal of Medicinal Chemistry, vol. 74, pp. 562-573. https://doi.org/10.1016/j.ejmech.2013.12.048
Vidadala, Rama Subba Rao ; Ojo, Kayode K. ; Johnson, Steven ; Zhang, Zhongsheng ; Leonard, Stephen E. ; Mitra, Arinjay ; Choi, Ryan ; Reid, Molly C. ; Keyloun, Katelyn R. ; Fox, Anna M W ; Kennedy, Mark ; Silver-Brace, Tiffany ; Hume, Jen C C ; Kappe, Stefan ; Verlinde, Christophe L M J ; Fan, Erkang ; Merritt, Ethan A. ; Van Voorhis, Wesley C. ; Maly, Dustin J. / Development of potent and selective Plasmodium falciparum calcium-dependent protein kinase 4 (PfCDPK4) inhibitors that block the transmission of malaria to mosquitoes. In: European Journal of Medicinal Chemistry. 2014 ; Vol. 74. pp. 562-573.
@article{be35eeb504eb40f98330d225562a2723,
title = "Development of potent and selective Plasmodium falciparum calcium-dependent protein kinase 4 (PfCDPK4) inhibitors that block the transmission of malaria to mosquitoes",
abstract = "Malaria remains a major health concern for a large percentage of the world's population. While great strides have been made in reducing mortality due to malaria, new strategies and therapies are still needed. Therapies that are capable of blocking the transmission of Plasmodium parasites are particularly attractive, but only primaquine accomplishes this, and toxicity issues hamper its widespread use. In this study, we describe a series of pyrazolopyrimidine- and imidazopyrazine-based compounds that are potent inhibitors of PfCDPK4, which is a calcium-activated Plasmodium protein kinase that is essential for exflagellation of male gametocytes. Thus, PfCDPK4 is essential for the sexual development of Plasmodium parasites and their ability to infect mosquitoes. We demonstrate that two structural features in the ATP-binding site of PfCDPK4 can be exploited in order to obtain potent and selective inhibitors of this enzyme. Furthermore, we demonstrate that pyrazolopyrimidine-based inhibitors that are potent inhibitors of the in vitro activity of PfCDPK4 are also able to block Plasmodium falciparum exflagellation with no observable toxicity to human cells. This medicinal chemistry effort serves as a valuable starting point in the development of safe, transmission-blocking agents for the control of malaria.",
keywords = "Exflagellation, PfCDPK1, PfCDPK4, Plasmodium falciparum, Pyrazolopyrimidine",
author = "Vidadala, {Rama Subba Rao} and Ojo, {Kayode K.} and Steven Johnson and Zhongsheng Zhang and Leonard, {Stephen E.} and Arinjay Mitra and Ryan Choi and Reid, {Molly C.} and Keyloun, {Katelyn R.} and Fox, {Anna M W} and Mark Kennedy and Tiffany Silver-Brace and Hume, {Jen C C} and Stefan Kappe and Verlinde, {Christophe L M J} and Erkang Fan and Merritt, {Ethan A.} and {Van Voorhis}, {Wesley C.} and Maly, {Dustin J.}",
year = "2014",
month = "3",
day = "3",
doi = "10.1016/j.ejmech.2013.12.048",
language = "English (US)",
volume = "74",
pages = "562--573",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - Development of potent and selective Plasmodium falciparum calcium-dependent protein kinase 4 (PfCDPK4) inhibitors that block the transmission of malaria to mosquitoes

AU - Vidadala, Rama Subba Rao

AU - Ojo, Kayode K.

AU - Johnson, Steven

AU - Zhang, Zhongsheng

AU - Leonard, Stephen E.

AU - Mitra, Arinjay

AU - Choi, Ryan

AU - Reid, Molly C.

AU - Keyloun, Katelyn R.

AU - Fox, Anna M W

AU - Kennedy, Mark

AU - Silver-Brace, Tiffany

AU - Hume, Jen C C

AU - Kappe, Stefan

AU - Verlinde, Christophe L M J

AU - Fan, Erkang

AU - Merritt, Ethan A.

AU - Van Voorhis, Wesley C.

AU - Maly, Dustin J.

PY - 2014/3/3

Y1 - 2014/3/3

N2 - Malaria remains a major health concern for a large percentage of the world's population. While great strides have been made in reducing mortality due to malaria, new strategies and therapies are still needed. Therapies that are capable of blocking the transmission of Plasmodium parasites are particularly attractive, but only primaquine accomplishes this, and toxicity issues hamper its widespread use. In this study, we describe a series of pyrazolopyrimidine- and imidazopyrazine-based compounds that are potent inhibitors of PfCDPK4, which is a calcium-activated Plasmodium protein kinase that is essential for exflagellation of male gametocytes. Thus, PfCDPK4 is essential for the sexual development of Plasmodium parasites and their ability to infect mosquitoes. We demonstrate that two structural features in the ATP-binding site of PfCDPK4 can be exploited in order to obtain potent and selective inhibitors of this enzyme. Furthermore, we demonstrate that pyrazolopyrimidine-based inhibitors that are potent inhibitors of the in vitro activity of PfCDPK4 are also able to block Plasmodium falciparum exflagellation with no observable toxicity to human cells. This medicinal chemistry effort serves as a valuable starting point in the development of safe, transmission-blocking agents for the control of malaria.

AB - Malaria remains a major health concern for a large percentage of the world's population. While great strides have been made in reducing mortality due to malaria, new strategies and therapies are still needed. Therapies that are capable of blocking the transmission of Plasmodium parasites are particularly attractive, but only primaquine accomplishes this, and toxicity issues hamper its widespread use. In this study, we describe a series of pyrazolopyrimidine- and imidazopyrazine-based compounds that are potent inhibitors of PfCDPK4, which is a calcium-activated Plasmodium protein kinase that is essential for exflagellation of male gametocytes. Thus, PfCDPK4 is essential for the sexual development of Plasmodium parasites and their ability to infect mosquitoes. We demonstrate that two structural features in the ATP-binding site of PfCDPK4 can be exploited in order to obtain potent and selective inhibitors of this enzyme. Furthermore, we demonstrate that pyrazolopyrimidine-based inhibitors that are potent inhibitors of the in vitro activity of PfCDPK4 are also able to block Plasmodium falciparum exflagellation with no observable toxicity to human cells. This medicinal chemistry effort serves as a valuable starting point in the development of safe, transmission-blocking agents for the control of malaria.

KW - Exflagellation

KW - PfCDPK1

KW - PfCDPK4

KW - Plasmodium falciparum

KW - Pyrazolopyrimidine

UR - http://www.scopus.com/inward/record.url?scp=84894170842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894170842&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2013.12.048

DO - 10.1016/j.ejmech.2013.12.048

M3 - Article

VL - 74

SP - 562

EP - 573

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -